Novel therapeutic uses and formulations of botulinum neurotoxins: a patent review (2012 – 2014). (June 2015)

• Record Type: Journal Article
• Authors: Kane, Christopher D; Nuss, Jonathan E; Bavari, Sina
• Is Part Of: Expert opinion on therapeutic patents. Volume 25:Number 6(2015:Jun.)
• Page Start: 675
• Page End: 690
• Publication Date: 2015-06
• Subjects: Drugs -- Patents -- Periodicals; 615.10272
• DOI: 10.1517/13543776.2015.1030337
• Languages: English
• ISSNs: 1354-3776

Abstract

<abstract> <title> <x xml:space="preserve">Abstract</x> </title> <p> <bold> <italic>Introduction:</italic> </bold> Botulinum neurotoxins (BoNTs) are among the most toxic of known biological molecules and function as acetylcholine release inhibitors and neuromuscular blocking agents. Paradoxically, these properties also make them valuable therapeutic agents for the treatment of movement disorders, urological conditions and hypersecretory disorders. Greater understanding of their molecular mechanism of action and advances in protein engineering has led to significant efforts to improve and expand their function with a view towards broadening their therapeutic potential.</p> <p> <bold> <italic>Areas covered:</italic> </bold> Searches of Espacenet and Google Patent have revealed a number of patents related to BoNTs. This review will focus on novel therapeutic uses and formulations disclosed during 2012 – 2014. The seven patents discussed will include nanoformulations of FDA-approved BoNTs, additional BoNT subtypes and novel BoNT variants and chimeras created through protein engineering. Supporting patents and related publications are also briefly discussed.</p> <p> <bold> <italic>Expert opinion:</italic> </bold> The clinical and commercial success of BoNTs has prompted investigation into novel BoNTs or BoNT-mediated chimeras with promising <italic>in vitro</italic> results. Distinct strategies including the use of nanoformulations and targeted delivery have been implemented to identify new indication and improved functionality. Greater understanding of their systemic exposure, efficacy and safety profiles will be required for further development.</p> </abstract>